Skip to main content
Micha Levi on Muck Rack

Micha Levi

As seen in: Medscape, Clinical Leader
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Micha

Contact Micha, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety And Pharmacokinetics In LMIC Clinical Trials

|
By Micha Levi, Charles Wells
| Clinical Leader Verified
By Micha Levi, Ph.D., and Charles Wells, MD, Gates Medical Research Institute (Gates MRI) Tuberculosis (TB) and malaria, two infectious diseases whose burdens weigh the heaviest on low- and middle-income countries (LMICs), killed almost 2 million people in 2023.
Open in Who Shared Issue with article?

Fremanezumab Monthly, Quarterly Doses and Efficacy Responses

|
By Elizabeth Ludwig, Jill Fiedler-Kelly, Julie Passarell, Micha Levi
| Medscape Verified
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel In This Article Abstract and Introduction Abstract Objective: Exposure-response (E-R) models were developed to provide a description of the time-course of treatment effect for monthly and quarterly dosing regimens of fremanezumab.
Open in Who Shared Issue with article?
See all 2 articles